Mediclinic International plc appoints Chair Designate
Mediclinic International plc appoints Dame Inga Beale as Independent Non-executive Director and Chair Designate
Mediclinic, a leading international private healthcare services group, announces the appointment of Dame Inga Beale as an independent non-executive director and Chair Designate with effect from 26 March 2020. Following a handover period, Dame Inga will succeed Dr Edwin Hertzog as Chair upon his retirement at the conclusion of the Company’s annual general meeting on 22 July 2020.
Dame Inga has extensive business management and leadership experience, and was appointed in 2014 as the first female Chief Executive Officer of Lloyd's of London, the insurance and reinsurance market, a position which she held until 2018. She currently serves as an independent member of the global strategy board of Clyde & Co LLP and as an independent non-executive director on the boards of Crawford & Company and London First. In addition, Dame Inga serves on the London Mayor’s Business Advisory Board. She is also Patron of Insuring Women’s Futures and Chair of the UK HIV Commission. During her executive career, she held various senior leadership positions in Switzerland and internationally across the insurance sector, including at Converium, Zurich Insurance Group, Canopius and GE Insurance Solutions.
Dame Inga is a Chartered Insurer and studied economics and accounting. In 2017, she was appointed Dame Commander of the Order of the British Empire for services to the UK economy.
Dame Inga has also been appointed as a member of the Nomination Committee with effect from 26 March 2020.
Dr Edwin Hertzog, Chair of Mediclinic International, commented:
“The Board is delighted to welcome Dame Inga as an independent non-executive director and Chair Designate of the Company. She has a clear understanding of our strong culture and values and will also align readily with our business. Core to these matters are our stakeholder commitment to deliver sustainable high-quality healthcare services and our purpose to enhance the quality of life. Dame Inga will expertly lead the Board in pursuit of these objectives including the challenge if the COVID-19 pandemic continues to spread globally.”
Alan Grieve, the Company’s Senior Independent Director, who led the planned succession process, commented:
“I am very pleased with the outcome of the thorough and independent process conducted to identify a successor to Dr Hertzog. Dame Inga will contribute a wealth of business experience, both as a leader and role model. During her tenure at Lloyd’s of London she initiated large-scale digital and cultural transformation programmes and led its expansion into Dubai, China and India. Dame Inga also played a critical role in advancing diversity and inclusion initiatives across Lloyd’s and the international insurance sector.”
Dame Inga Beale commented:
“I am very pleased to be joining Mediclinic International, an organisation that puts patients at the heart of its business. The Group has a clear strategy and exciting long-term outlook under the leadership of Dr Ronnie Van der Merwe and his executive team. I look forward to working with the Board, the executive team and Mediclinic’s various stakeholders as the Company builds on the market-leading positions of its three divisions and adapts to the changing global healthcare environment.”
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
As at 1 March 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian Stock Exchange ("NSX") in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.